Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
  • Platform
  • Pipeline
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Connect

Press Releases

To view the webinar replay of “PRECISE-AD Phase 1b Blinded Interim Data Analysis"  Click Here

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Jan 17, 2019

ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences

Dec 18, 2018

ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek

Dec 17, 2018

ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board

Nov 20, 2018

ProMIS Neurosciences Issues Year-to Date Update, Highlighting 2018 Accomplishments

Nov 13, 2018

ProMIS Neurosciences Announces Third Quarter 2018 Results

Nov 6, 2018

ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease

Oct 31, 2018

ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias

Oct 11, 2018

ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease

Sep 17, 2018

ProMIS Neurosciences to Present at Extraordinary Futures Investment Conference

Sep 13, 2018

ProMIS Neurosciences Appoints James Kupiec, MD as Chief Medical Officer

  • arrow_back
  • 1…
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • arrow_forward
Linkedin Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy

Disclaimer

All statements and expressions are the sole opinion of the company and are subject to change without notice.  The Company is not liable for any investment decisions by its readers or subscribers.  It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies.  The information contained herein has been provided as an information service only.  The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained.  Investors are cautioned that they may lose all or a portion of their investment in this or any other company.

Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements".  Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.